System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK : the AMR-X framework
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Antimicrobial resistance (AMR) threatens human, animal, and environmental health. Acknowledging the urgency of addressing AMR, an opportunity exists to extend AMR action-focused research beyond the confines of an isolated biomedical paradigm. An AMR learning system, AMR-X, envisions a national network of health systems creating and applying optimal use of antimicrobials on the basis of their data collected from the delivery of routine clinical care. AMR-X integrates traditional AMR discovery, experimental research, and applied research with continuous analysis of pathogens, antimicrobial uses, and clinical outcomes that are routinely disseminated to practitioners, policy makers, patients, and the public to drive changes in practice and outcomes. AMR-X uses connected data-to-action systems to underpin an evaluation framework embedded in routine care, continuously driving implementation of improvements in patient and population health, targeting investment, and incentivising innovation. All stakeholders co-create AMR-X, protecting the public from AMR by adapting to continuously evolving AMR threats and generating the information needed for precision patient and population care.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
The Lancet. Microbe - (2024) vom: 28. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
AMR-X Collaborators [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1016/S2666-5247(24)00003-X |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369515595 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369515595 | ||
003 | DE-627 | ||
005 | 20240320234645.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240311s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/S2666-5247(24)00003-X |2 doi | |
028 | 5 | 2 | |a pubmed24n1337.xml |
035 | |a (DE-627)NLM369515595 | ||
035 | |a (NLM)38461831 | ||
035 | |a (PII)S2666-5247(24)00003-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a AMR-X Collaborators |e verfasserin |4 aut | |
245 | 1 | 0 | |a System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK |b the AMR-X framework |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 20.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
520 | |a Antimicrobial resistance (AMR) threatens human, animal, and environmental health. Acknowledging the urgency of addressing AMR, an opportunity exists to extend AMR action-focused research beyond the confines of an isolated biomedical paradigm. An AMR learning system, AMR-X, envisions a national network of health systems creating and applying optimal use of antimicrobials on the basis of their data collected from the delivery of routine clinical care. AMR-X integrates traditional AMR discovery, experimental research, and applied research with continuous analysis of pathogens, antimicrobial uses, and clinical outcomes that are routinely disseminated to practitioners, policy makers, patients, and the public to drive changes in practice and outcomes. AMR-X uses connected data-to-action systems to underpin an evaluation framework embedded in routine care, continuously driving implementation of improvements in patient and population health, targeting investment, and incentivising innovation. All stakeholders co-create AMR-X, protecting the public from AMR by adapting to continuously evolving AMR threats and generating the information needed for precision patient and population care | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
700 | 1 | |a Abel, Kathryn |e investigator |4 oth | |
700 | 1 | |a Agnew, Emily |e investigator |4 oth | |
700 | 1 | |a Amos, James |e investigator |4 oth | |
700 | 1 | |a Armstrong, Natalie |e investigator |4 oth | |
700 | 1 | |a Armstrong-James, Darius |e investigator |4 oth | |
700 | 1 | |a Ashfield, Thomas |e investigator |4 oth | |
700 | 1 | |a Aston, Stephen |e investigator |4 oth | |
700 | 1 | |a Baillie, J Kenneth |e investigator |4 oth | |
700 | 1 | |a Baldwin, Steven |e investigator |4 oth | |
700 | 1 | |a Barlow, Gavin |e investigator |4 oth | |
700 | 1 | |a Bartle, Victoria |e investigator |4 oth | |
700 | 1 | |a Bielicki, Julia |e investigator |4 oth | |
700 | 1 | |a Brown, Colin |e investigator |4 oth | |
700 | 1 | |a Carrol, Enitan |e investigator |4 oth | |
700 | 1 | |a Clements, Michelle |e investigator |4 oth | |
700 | 1 | |a Cooke, Graham |e investigator |4 oth | |
700 | 1 | |a Dane, Aaron |e investigator |4 oth | |
700 | 1 | |a Dark, Paul |e investigator |4 oth | |
700 | 1 | |a Day, Jeremy |e investigator |4 oth | |
700 | 1 | |a de-Soyza, Anthony |e investigator |4 oth | |
700 | 1 | |a Dowsey, Andrew |e investigator |4 oth | |
700 | 1 | |a Evans, Stephanie |e investigator |4 oth | |
700 | 1 | |a Eyre, David |e investigator |4 oth | |
700 | 1 | |a Felton, Timothy |e investigator |4 oth | |
700 | 1 | |a Fowler, Tom |e investigator |4 oth | |
700 | 1 | |a Foy, Robbie |e investigator |4 oth | |
700 | 1 | |a Gannon, Karen |e investigator |4 oth | |
700 | 1 | |a Gerada, Alessandro |e investigator |4 oth | |
700 | 1 | |a Goodman, Anna |e investigator |4 oth | |
700 | 1 | |a Harman, Tracy |e investigator |4 oth | |
700 | 1 | |a Hayward, Gail |e investigator |4 oth | |
700 | 1 | |a Holmes, Alison |e investigator |4 oth | |
700 | 1 | |a Hopkins, Susan |e investigator |4 oth | |
700 | 1 | |a Howard, Philip |e investigator |4 oth | |
700 | 1 | |a Howard, Alexander |e investigator |4 oth | |
700 | 1 | |a Hsia, Yingfen |e investigator |4 oth | |
700 | 1 | |a Knight, Gwen |e investigator |4 oth | |
700 | 1 | |a Lemoine, Nick |e investigator |4 oth | |
700 | 1 | |a Koh, James |e investigator |4 oth | |
700 | 1 | |a Macgowan, Alasdair |e investigator |4 oth | |
700 | 1 | |a Marwick, Charis |e investigator |4 oth | |
700 | 1 | |a Moore, Catrin |e investigator |4 oth | |
700 | 1 | |a O'Brien, Seamus |e investigator |4 oth | |
700 | 1 | |a Oppong, Raymond |e investigator |4 oth | |
700 | 1 | |a Peacock, Sharon |e investigator |4 oth | |
700 | 1 | |a Pett, Sarah |e investigator |4 oth | |
700 | 1 | |a Pouwels, Koen |e investigator |4 oth | |
700 | 1 | |a Queree, Chris |e investigator |4 oth | |
700 | 1 | |a Rahman, Najib |e investigator |4 oth | |
700 | 1 | |a Sculpher, Mark |e investigator |4 oth | |
700 | 1 | |a Shallcross, Laura |e investigator |4 oth | |
700 | 1 | |a Sharland, Michael |e investigator |4 oth | |
700 | 1 | |a Singh, Jasvinder |e investigator |4 oth | |
700 | 1 | |a Stoddart, Karen |e investigator |4 oth | |
700 | 1 | |a Thomas-Jones, Emma |e investigator |4 oth | |
700 | 1 | |a Townsend, Andrew |e investigator |4 oth | |
700 | 1 | |a Ustianowski, Andrew |e investigator |4 oth | |
700 | 1 | |a Van Staa, Tjeerd |e investigator |4 oth | |
700 | 1 | |a Walker, Sarah |e investigator |4 oth | |
700 | 1 | |a White, Peter |e investigator |4 oth | |
700 | 1 | |a Wilson, Paul |e investigator |4 oth | |
700 | 1 | |a Buchan, Iain |e investigator |4 oth | |
700 | 1 | |a Woods, Beth |e investigator |4 oth | |
700 | 1 | |a Bower, Peter |e investigator |4 oth | |
700 | 1 | |a Llewelyn, Martin |e investigator |4 oth | |
700 | 1 | |a Hope, William |e investigator |4 oth | |
773 | 0 | 8 | |i Enthalten in |t The Lancet. Microbe |d 2020 |g (2024) vom: 28. Feb. |w (DE-627)NLM312200277 |x 2666-5247 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:28 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2666-5247(24)00003-X |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 28 |c 02 |